Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$35.48 USD
+0.65 (1.87%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $35.46 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Income Statements
Fiscal Year end for Harmony Biosciences Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 582 | 438 | 305 | 160 | 6 |
Cost Of Goods | 121 | 83 | 56 | 28 | 2 |
Gross Profit | 461 | 354 | 250 | 132 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 269 | 234 | 162 | 115 | 150 |
Income After Depreciation & Amortization | 192 | 120 | 88 | 17 | -146 |
Non-Operating Income | 5 | 0 | -26 | -26 | 0 |
Interest Expense | 24 | 16 | 24 | 28 | 6 |
Pretax Income | 173 | 105 | 37 | -37 | -152 |
Income Taxes | 45 | -77 | 3 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 129 | 181 | 35 | -37 | -152 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 129 | 181 | 35 | -37 | -152 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 216 | 145 | 109 | 30 | -142 |
Depreciation & Amortization (Cash Flow) | 24 | 25 | 21 | 13 | 4 |
Income After Depreciation & Amortization | 192 | 120 | 88 | 17 | -146 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.37 | 61.10 | 59.21 | 25.77 | NA |
Diluted EPS Before Non-Recurring Items | 2.13 | 3.00 | 2.07 | 0.21 | NA |
Diluted Net EPS (GAAP) | 2.13 | 2.97 | 0.58 | -2.48 | NA |
Fiscal Year end for Harmony Biosciences Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 172.81 | 154.62 | 168.41 | 160.27 |
Cost Of Goods | NA | 32.14 | 27.48 | 43.15 | 32.30 |
Gross Profit | NA | 140.67 | 127.13 | 125.26 | 127.97 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 119.31 | 75.10 | 85.07 | 63.46 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 21.36 | 52.03 | 40.19 | 64.51 |
Non-Operating Income | NA | 4.74 | 4.29 | 0.19 | -9.77 |
Interest Expense | NA | 4.40 | 4.54 | 15.43 | 2.91 |
Pretax Income | NA | 21.69 | 51.79 | 39.69 | 51.83 |
Income Taxes | NA | 10.10 | 13.45 | 13.08 | 13.37 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 11.59 | 38.33 | 26.61 | 38.46 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 11.59 | 38.33 | 26.61 | 38.46 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 57.54 | 57.60 | 58.85 | 60.68 |
Diluted EPS Before Non-Recurring Items | NA | 0.20 | 0.67 | 0.45 | 0.63 |
Diluted Net EPS (GAAP) | NA | 0.20 | 0.67 | 0.46 | 0.63 |